GFAP Antibody - #DF6040
(39)
(22)
| Product: | GFAP Antibody |
| Catalog: | DF6040 |
| Description: | Rabbit polyclonal antibody to GFAP |
| Application: | WB IHC IF/ICC |
| Cited expt.: | WB, IHC, IF/ICC |
| Reactivity: | Human, Mouse, Rat |
| Prediction: | Bovine, Horse, Rabbit, Chicken |
| Mol.Wt.: | 45-50kDa; 50kD(Calculated). |
| Uniprot: | P14136 |
| RRID: | AB_2838012 |
Related Downloads
Protocols
Product Info
Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:500-1:1000
*The optimal dilutions should be determined by the end user.
*Tips:
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(100%), Horse(100%), Rabbit(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
GFAP Antibody detects endogenous levels of total GFAP.
RRID:
AB_2838012
Cite Format: Affinity Biosciences Cat# DF6040, RRID:AB_2838012.
Cite Format: Affinity Biosciences Cat# DF6040, RRID:AB_2838012.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:
Fold/Unfold
wu:fb34h11; ALXDRD; cb345; etID36982.3; FLJ42474; FLJ45472; GFAP; GFAP_HUMAN; gfapl; Glial fibrillary acidic protein; Intermediate filament protein; wu:fk42c12; xx:af506734; zgc:110485;
Immunogens
Immunogen:
A synthesized peptide derived from human GFAP, corresponding to a region within C-terminal amino acids.
Uniprot:
Gene(ID):
Expression:
Description:
The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. Major types of intermediate filaments are specifically expressed in particular cell types: cytokeratins in epithelial cells, glial fibrillary acidic protein (GFAP) in glial cells, desmin in skeletal, visceral, and certain vascular smooth muscle cells, vimentin in cells of mesenchymal origin, and neurofilaments in neurons. GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape (1). In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes (2). In addition, GFAP intermediate filaments are also present in non-myelin-forming Schwann cells in the peripheral nervous system (3).
Sequence:
- P14136 GFAP_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM
Predictions
Predictions:
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
Species
Results
Score
Horse
100
Bovine
100
Chicken
100
Rabbit
100
Pig
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence
High(score>80) Medium(80>score>50) Low(score<50) No confidence
Research Backgrounds
Function:
GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
PTMs:
Phosphorylated by PKN1.
Subcellular Location:
Cytoplasm.
Note: Associated with intermediate filaments.
Tissue Specificity:
Expressed in cells lacking fibronectin.
Family&Domains:
Belongs to the intermediate filament family.
Research Fields
· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)
References
1). Neurogenesis promoted by the CD200/CD200R signaling pathway following treadmill exercise enhances post-stroke functional recovery in rats. BRAIN BEHAVIOR AND IMMUNITY, 2019
(PubMed: 31513876)
[IF=8.8]
Application: IF/ICC Species: rat Sample: astrocytes
Fig. 5.| The expression of CD200 and CD200R was up-regulated induced by treadmill exercise after stroke in rats.The effect of treadmill exercise on the protein levels of CD200 and CD200R in the ischemic cortex (A-C) and hippocampus (D-F) at 7 and 28 days after tMCAO. CD200R staining shows protein expression at 7 and 28 days after treadmill exercise post-stroke (G). CD200R colocalizes with activated microglia (Iba1+cells, white arrows), not colocalizes with neural stem cells (Nestin+ cells) and astrocytes (GFAP+ cells), Scale bar: 50 μm. N = 4. Results are showed as means ± SEM. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the Sham group. *P < 0.05, ** P < 0.01, *** P < 0.001 versus the tMCAO group.
2). Multi-targeted nanogel drug delivery system alleviates neuroinflammation and promotes spinal cord injury repair. Materials today. Bio, 2025
(PubMed: 39935893)
[IF=8.7]
3). NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's disease via ATF4-dependent mitochondrial UPR. Cell death & disease, 2024
(PubMed: 39394148)
[IF=8.1]
4). Inhibition of abnormal C/EBPβ/α-Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease-like pathology. Aging cell, 2023
(PubMed: 37614147)
[IF=8.0]
5). Effects of hydrogen-rich saline in neuroinflammation and mitochondrial dysfunction in rat model of sepsis-associated encephalopathy. Journal of Translational Medicine, 2022
(PubMed: 36435787)
[IF=7.4]
Application: WB Species: Rat Sample:
Fig. 8
Effects of HRS treatment on protein expressions in septic rats 48 h after LPS challenge. A Representative images of protein expression levels by western blot analysis in each group. B–E Statistical representation of relative protein expressions of GFAP, IBA-1, BCL-2 and BAX; respectively. All data are presented as mean ± SD ****p < 0.0001, ***p < 0.001, **p < 0.005, *p < 0.05. HRS Hydrogen-rich saline, LPS Lipopolysaccharide, GFAP Glial fibrillary acidic protein, IBA-1 Ionised calcium binding adaptor molecule 1, BCL-2 B-cell lymphoma 2
6). The effect of tau K677 lactylation on ferritinophagy and ferroptosis in Alzheimer's disease. Free radical biology & medicine, 2024
(PubMed: 39307193)
[IF=7.1]
7). Relationship between Aspartame-Induced Cerebral Cortex Injury and Oxidative Stress, Inflammation, Mitochondrial Dysfunction, and Apoptosis in Sprague Dawley Rats. Antioxidants (Basel, Switzerland), 2023
(PubMed: 38275622)
[IF=7.0]
8). Feruloylated oligosaccharides ameliorate MPTP-induced neurotoxicity in mice by activating ERK/CREB/BDNF/TrkB signalling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023
(PubMed: 36288652)
[IF=6.7]
9). Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020
(PubMed: 32182488)
[IF=6.0]
Application: IF/ICC Species: Mouse Sample: BV2 and C6 cells
Fig. 4. Effects of compounds on GFAP and Iba-1 expression in the LPS-induced astrocytes (C6, treated with 10 mg/mL of LPS) and microglia (BV2, treated with 1 mg/mL of LPS). A.
Representative fluorescence microscopy images of GFAP immunostaining (Magnification 20). B. Representative fluorescence microscopy images of Iba-1 immunostaining
(Magnification 40). C. Histograms show relative changes of GFAP expressed as mean ± SD of the three independent experiments (n ¼ 3). Ctrl. ¼ Control, LPS ¼ Lipopolysaccharide
(10 mg/mL); 3, 13, 16 ¼ treatments by compounds 3, 13, 16 (20 mM) along with LPS (10 mg/mL). D. Histograms show relative changes of Iba-1 expressed as mean ± SD of the three
independent experiments (n ¼ 3). All the data were analyzed using Image Pro Plus and expressed as a percent of LPS group values (fluorescence intensity). (#) Significant difference
(##p < 0.01, ###p < 0.001) vs. control and (*) significant difference (*p < 0.05 and **p < 0.01) vs. LPS.
10). ICU patient-on-a-chip emulating orchestration of mast cells and cerebral organoids in neuroinflammation. Communications biology, 2024
(PubMed: 39639082)
[IF=5.9]
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.